AIRA Matrix vs Ibex Medical Analytics (2026)
AIRA Matrix and Ibex Medical Analytics both apply deep learning to pathology slides, for different buyers. Ibex sells AI that reads H&E whole slide images for prostate, breast and gastric cancer on its Ibex 4 platform and returns findings into laboratories' existing image management and laboratory systems through partners such as Roche, Philips, Proscia, Sectra and Fujifilm. Its breast IHC models for HER2, ER, PR and Ki67 carry CE IVDR certification, one prostate product is FDA 510(k) cleared as a second read for biopsies first diagnosed as benign, and the company says its AI runs at hundreds of live sites, including NHS Wales and UPMC. AIRA Matrix, based in Thane, India, labels its products Research Use Only. AIRATox triages and quantifies findings in toxicology studies on a self supervised model trained on 130,000 whole slide images across six species, PredTox predicts organ toxicity from compound data, and AIRADHI manages GLP studies. AIRAProstate classifies Gleason patterns on prostate biopsies and prostatectomies, and AIRAQc flags slides with artifacts against thresholds a lab sets. Peer reviewed studies with Johns Hopkins, Radboud University Medical Center and LabCorp cover its models. For clinical cancer diagnosis with a published regulatory position, Ibex carries the clearances and a multi site reader study; for preclinical toxicology and compound screening, AIRA Matrix sells tools built for that work. Ibex publishes a business associate addendum, a data protection addendum, a subprocessor list and certifications including ISO 27001 and HITRUST on its trust center, while AIRA Matrix names no security attestation or HIPAA position. Neither publishes a price.
- AIRATox screens, triages and quantifies findings in toxicology studies across species, on a model trained on 130,000 whole slide images from more than 40 labs.
- PredTox predicts in vivo organ toxicity from compound data on a desktop platform, keeping molecule information inside the organization.
- AIRADHI manages GLP studies with audit trails and electronic signatures for 21 CFR Part 11, in the cloud or on premise.
- AIRAQc accepts or flags each slide for rescanning against artifact thresholds the lab sets, with 95% sensitivity and 96% specificity reported.
- Prostate cancer models studied with Johns Hopkins and in a Radboud evaluation of Gleason algorithms on outside data.
- Ibex Prostate, the Ibex Breast Suite and Ibex Gastric read H&E slides and return findings into the lab's image management and laboratory systems.
- Galen Second Read is FDA 510(k) cleared to flag prostate biopsies first diagnosed as benign for another look, and breast IHC models carry CE IVDR certification.
- A reader study of 772 cases with 12 pathologists at four sites supports the cleared prostate product.
- Partners include Roche, Philips, Proscia, Sectra and Fujifilm, with the AI at hundreds of live sites such as NHS Wales, UPMC and Alverno Laboratories.
- A trust center publishes the business associate addendum, data protection addendum and subprocessor list, beside ISO 27001 and HITRUST.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AIRA Matrix and Ibex Medical Analytics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AIRA Matrix | Ibex Medical Analytics |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | Not recorded | 2016 |
| Headquarters | Thane, Maharashtra, India | Tel Aviv, Israel |
| Website | airamatrix.com | ibex-ai.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
AIRA Matrix, based in Thane, India, sells deep learning pathology tools labeled Research Use Only: AIRATox, PredTox and AIRADHI for preclinical toxicology and drug development, AIRAProstate for prostate cancer analysis and AIRAQc for slide quality control, in the cloud or on premise. Its algorithms are offered through Sectra, Techcyte, Gestalt and Lumea, and peer reviewed studies with Johns Hopkins, Radboud University Medical Center and LabCorp cover its models. No security attestation, HIPAA position or price is published.
Source: AI Health Index, November 2026
Ibex Medical Analytics sells AI that reads H&E whole slide images for prostate, breast and gastric cancer on its Ibex 4 platform, delivered into laboratories' existing systems through partners such as Roche, Philips, Proscia, Sectra and Fujifilm. One prostate product is FDA cleared as a second read and its breast IHC models carry CE IVDR certification, and its trust center publishes a business associate addendum, data protection addendum and subprocessor list, with the service on AWS. No price is published.
Source: AI Health Index, November 2026
Questions buyers ask
How does Ibex compare with AIRA Matrix?
Both apply deep learning to pathology slides. Ibex sells clinical AI for prostate, breast and gastric cancer, with one FDA cleared prostate product and CE IVDR certified breast models, delivered through laboratories' existing image management systems. AIRA Matrix labels its products Research Use Only and concentrates on preclinical toxicology and drug development, alongside prostate cancer analysis and slide quality control. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified November 16, 2026. No vendor pays for placement.
How much do AIRA Matrix and Ibex cost?
Neither publishes a price. AIRA Matrix offers image analysis as a service, pay per use for small projects or by subscription, beside its software. Ibex delivers its AI through image management partners such as Roche, Philips and Sectra, and its business associate addendum is incorporated into its general terms. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified November 16, 2026. No vendor pays for placement.
Are AIRA Matrix or Ibex FDA cleared?
Ibex holds one FDA 510(k) clearance (K241232, January 2025) for Galen Second Read, which flags prostate biopsies first diagnosed as benign for another look, on the Philips Ultra Fast Scanner; its site labels Ibex Prostate research use only in the United States. AIRA Matrix has no FDA clearance and labels its products Research Use Only. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified November 16, 2026. No vendor pays for placement.
What evidence do AIRA Matrix and Ibex publish?
Ibex's cleared prostate product rests on a standalone study of 347 benign diagnosed cases and a reader study of 772 cases with 12 pathologists at four sites, in which sensitivity rose from 90.5% to 93.9% with the device. AIRA Matrix's prostate and toxicology models appear in peer reviewed studies with Johns Hopkins, Radboud University Medical Center, Experimental Pathology Laboratories and LabCorp, coauthored by its staff. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified November 16, 2026. No vendor pays for placement.
How do AIRA Matrix and Ibex handle security and data?
Ibex runs on AWS, publishes its business associate addendum, data protection addendum and subprocessor list, and names ISO 27001, HITRUST and other certifications, with reports on request. AIRA Matrix names no security attestation or HIPAA position, and offers cloud or on premise deployment, with PredTox running on the desktop. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified November 16, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Neither AIRA Matrix nor Ibex Medical Analytics publishes a price or results by site, scanner or patient group for its AI.
AIRA Matrix labels every product Research Use Only while its prostate pages describe diagnosis and treatment planning, names no security attestation beyond an ISO 9001 quality certificate, states no HIPAA position and names no host for its cloud deployment.
Ibex's FDA clearance covers one prostate product as a second read for biopsies first diagnosed as benign, on one scanner, while its site labels Ibex Prostate research use only in the United States without naming the cleared product. Its security reports are available on request rather than open.